Sanofi Reports Results of Isatuximab Combination Therapy in P-III ICARIA-MM Study for Relapsed/Refractory Multiple Myeloma #ASCO2019

 Sanofi Reports Results of Isatuximab Combination Therapy in P-III ICARIA-MM Study for Relapsed/Refractory Multiple Myeloma #ASCO2019

Sanofi Reports Results of Isatuximab Combination Therapy in P-III ICARIA-MM Study for Relapsed/Refractory Multiple Myeloma #ASCO2019

Shots:

  • The P-III ICARIA-MM study results involve assessing of Isatuximab (10mg/kg, qw) + pomalidomide and dexamethasone (pom-dex) vs pom-dex in 307 patients with r/r multiple myeloma across 24 countries
  • The P-III ICARIA-MM study result: improvement in m-PFS (11.53mos. vs 6.47 mos.); ORR (60% vs 35%); VGPR rate (31.8% vs 8.5%); DOR (13.27mos. vs 11.07mos); median time to first response (35 days vs 58 days), presented at ASCO 2019 in Chicago
  • Isatuximab is a mAb targeting specific epitope on the CD38 receptor, designed to promote apoptosis & immunomodulatory activity, currently being evaluated in multiple P-III studies for multiple myeloma. EMA has accepted its MAA in Q2’19 and Sanofi has also filed FDA’s BLA for RRMM

Click here to read full press release/ article | Ref: Sanofi | Image: Etoile

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post